Nevro Corp. (NVRO) announced Monday morning that it has received approval from the FDA for its Senza II Spinal Cord Stimulation System delivering HF10 therapy.
Nevro gapped up sharply Monday and has spiked higher in early trade. The stock is now up 11.94 at $83.03 on above average volume. Nevro has jumped to a 2-month high.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com